Surgical posterior vitreous detachment combined with gas/air tamponade for treating macular edema associated with branch retinal vein occlusion: retinal tomography and visual outcome

2001 ◽  
Vol 239 (10) ◽  
pp. 729-732 ◽  
Author(s):  
Shizuya Saika ◽  
Takeshi Tanaka ◽  
Takeshi Miyamoto ◽  
Yoshitaka Ohnishi
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Posterior Vitreous Detachment ◽  
Visual Outcome ◽  
Vitreous Detachment ◽  
Vein Occlusion ◽  
Air Tamponade

EFFICACY OF COMBINED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE IN PATIENTS WITH NON-RESOLVING MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

2021 ◽  
pp. 48-49
Author(s):  
Haniyaa Mufti ◽  
Syed Tariq Qureshi ◽  
Birjees Hakak
Keyword(s):  
Combination Therapy ◽  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Common Adverse Effect ◽  
Visual Outcome ◽  
Intravitreal Injections ◽  
Therapeutic Effects ◽  
Vein Occlusion

Purpose: To study the effects of combined intravitreal injections of bevacizumab (IVB) and triamcinolone acetonide (IVTA) in patients with non-resolving macular edema (ME) secondary to Branch Retinal Vein Occlusion (BRVO). Methods: In a prospective observational study, 50 pseudophakic eyes of BRVO patients with non-resolving central macular edema who had received more than 3 doses of IVB previously were injected with combination therapy of 1.25 mg/0.05 ml IVB and 4 mg of IVTA and followed up for 6 months with best corrected visual acuity(BCVA), intraocular pressure(IOP) and central macular thickness(CMT) Results: The mean BCVA was logMAR 0.75±0.25 at baseline and 0.65±0.15, 0.48±0.20, and 0.22±0.25 at 6weeks, 3 months and 6 months respectively. Mean CMT at baseline was 668.32±254.66 and 434.43±99.55, 243.22±58.92, and 220.83±42.60 at 6 weeks, 3 months and 6 months respectively. Baseline IOP measured was 16.5±3.1 mmHg which progressed to 19.6±3.4mmHg and 21.4±2.8mmHg at 6 weeks and 3 months respectively and decreased to 17.3±2.2 at 6 months. The most common adverse effect seen was increase in IOP in 24(48%)patients, out of which 3(6%) patients needed to start anti-glaucoma medication (AGM). 3(6%) patients had sub-conjunctival hemorrhage(SCH). Conclusion: The prolonged therapeutic effects of combination therapy leads to outstanding anatomical and visual outcome in non resolving ME due to BRVO, with fewer doses and thus fewer adverse effects.

scholarly journals The effect of posterior vitreous detachment induced by intravitreal injections on macular edema with retinal vein occlusion

2021 ◽  
Vol 4 (2) ◽  
pp. 83
Author(s):  
Dorukcan Akincioglu ◽  
Murat Kucukevcilioglu ◽  
Ali Hakan Durukan
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Demographic Data ◽  
Posterior Vitreous Detachment ◽  
Binary Logistic Regression ◽  
Categorical Variables ◽  
Binary Logistic Regression Analysis ◽  
Vitreous Detachment ◽  
Vein Occlusion ◽  
Treatment Naïve

Introduction: To evaluate whether posterior vitreous detachment (PVD) improves treatment outcomes.Methods:The medical records of  treatment-naive patients followed up for a minimum of six months due to retinal vein occlusion between January 2007 and January 2016 were reviewed. Patients with initial PVD were excluded. Correlation analysis and binary logistic regression analysis were used to determine the relationship between categorical variables and treatment outcomes. A subgroup analysis (steroids vs anti-VEGFs) was also performed.Results: The study included 95 eyes of 95 patients with macular edema due to retinal vein occlusion. Patients in both groups [central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO)] were similar in terms of demographic data and showed similar improvement during the study. The patients who underwent intravitreal steroid injection (IVD or IVTA) were 12.35 times (95% CI: 4.03-37.85) more likely to develop PVD. The patients in steroid group had a statistically significantly high correlation with visual and anatomic improvements, especially after 5 months of follow-up. The median time of PVD was 5 months (2-11).Conclusion: Commonly used drugs in intravitreal pharmacotherapy induce PVD, which plays an important role for the treatment of underlying macular edema.

Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment

2003 ◽  
Vol 242 (3) ◽  
pp. 223-228 ◽  
Author(s):  
Jérôme Charbonnel ◽  
Agnès Glacet-Bernard ◽  
Jean-François Korobelnik ◽  
Emilienne Nyouma-Moune ◽  
Constantin J. Pournaras ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Posterior Vitreous Detachment ◽  
Vitreous Detachment ◽  
Vein Occlusion

scholarly journals Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy

2019 ◽  
Vol 258 (1) ◽  
pp. 49-56 ◽  
Author(s):  
Misa Suzuki ◽  
Norihiro Nagai ◽  
Sakiko Minami ◽  
Toshihide Kurihara ◽  
Mamoru Kamoshita ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Visual Outcome ◽  
University Hospital ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Department Of Ophthalmology ◽  
Clinical Records ◽  
Endothelial Growth Factor

Abstract Purpose To determine the predictive factors for recurrent macular edema due to branch retinal vein occlusion (BRVO) during intravitreal ranibizumab (IVR) monotherapy. Methods Clinical records were retrospectively reviewed for 65 patients (mean age 66.5 years, 65 eyes) who were diagnosed with macular edema due to BRVO and treated with IVR monotherapy for 12 months at the Medical Retina Division, Department of Ophthalmology, Keio University Hospital between October 2013 and August 2017. Best-corrected visual acuity (BCVA), fundus findings, and sectional optical coherence tomography (OCT) images were analyzed. Results Overall BCVA and central retinal thickness (CRT) improved (all p < 0.01). BCVA at 12 months was significantly worse in patients with recurrent macular edema (40 eyes [61.5%]) (p < 0.01) than in those without, while CRT decreased and was comparable in both groups at 12 months. Logistic regression analyses showed association of recurrence with disorganization of the retinal inner layer (DRIL) temporal to the fovea at baseline (odds ratio = 7.74; 95% confidence interval 1.62–37.08, p = 0.01), after adjusting for age, gender, and initial CRT. Conclusion Recurrent macular edema due to BRVO affects visual outcome and is associated with initial DRIL temporal to the fovea, evaluated using OCT sectional images before treatments. DRIL may facilitate determination of follow-up schedules in clinical practice.

scholarly journals Consecutive Macular Edema and Visual Outcome in Branch Retinal Vein Occlusion

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Sung Uk Baek ◽  
Soon Il Kwon ◽  
In Won Park ◽  
Kyung Jun Choi
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Intravitreal Bevacizumab ◽  
Visual Outcome ◽  
Clinical Trial Registration ◽  
Sacred Heart ◽  
Intravitreal Bevacizumab Injection ◽  
Vein Occlusion ◽  
Institutional Review

Purposes. The study introduced the concept of “consecutive macular edema” and evaluated the validity of visual outcome in macular edema (ME) secondary to branch retinal vein occlusion (BRVO).Methods. Patients were categorized into the gainer group and the nongainer group according to the final visual acuity. We analyzed clinical characteristics involving total and consecutive duration of ME between the two groups.Results. Among the total 71 eyes of 71 patients, intravitreal bevacizumab injection (26 patients), triamcinolone (21), and natural course (33) were enrolled. The consecutive duration of ME was shorter in the gainer group than in the nongainer group (3.33 ± 1.50 and 5.24 ± 2.39 months;P=0.000). After exclusion of macular ischemia, consecutive duration of ME in gainer group was also significantly shorter than in nongainer group (3.62 ± 1.60 and 6.11 ± 4.20 months;P=0.010).Conclusions. The duration of ME in the nongainer group was longer than in the gainer group. In particular, the consecutive duration was an important factor in determining the final visual outcome.Clinical Trial Registration. Approval by Hallym University Sacred Heart Hospital Institutional Review Board/Ethics Committee was obtained for this retrospective study.

Sign in / Sign up

Export Citation Format

Share Document